Phase 3 (ARMOR3-SV) lasted from June 2015 to November 2016, and it was a study of galeterone compared to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic castration-resistant prostate cancer [130,131]. The gene discussed is AR; the disease is prostate carcinoma.